University of Illinois
Chicago IL
MD - Medicine
1971
University of Wisconsin
Madison WI
BS - Liberal Arts
1967
Nanoscale Mixed-Ligand Metal-Organic Framework for X-ray Stimulated Cancer Therapy.
Nanoscale Mixed-Ligand Metal-Organic Framework for X-ray Stimulated Cancer Therapy. J Am Chem Soc. 2024 Nov 20.
PMID: 39565960
Bifunctional Metal-Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio-Immunotherapy.
Bifunctional Metal-Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio-Immunotherapy. Angew Chem Int Ed Engl. 2024 Oct 07; e202417027.
PMID: 39375150
Multifunctional Nanomaterials Mediate Cholesterol Depletion for Cancer Treatment.
Multifunctional Nanomaterials Mediate Cholesterol Depletion for Cancer Treatment. Angew Chem Int Ed Engl. 2024 Nov 11; 63(46):e202412844.
PMID: 39146242
Two decades of advances in clinical oncology - lessons learned and future directions.
Two decades of advances in clinical oncology - lessons learned and future directions. Nat Rev Clin Oncol. 2024 Nov; 21(11):771-780.
PMID: 39354161
Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance.
Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance. Clin Cancer Res. 2024 Oct 01; 30(19):4450-4463.
PMID: 38691100
YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production.
YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. J Clin Invest. 2024 Sep 26.
PMID: 39325547
Digitonin-Loaded Nanoscale Metal-Organic Framework for Mitochondria-Targeted Radiotherapy-Radiodynamic Therapy and Disulfidptosis.
Digitonin-Loaded Nanoscale Metal-Organic Framework for Mitochondria-Targeted Radiotherapy-Radiodynamic Therapy and Disulfidptosis. Adv Mater. 2024 Sep 10; e2405494.
PMID: 39252688
Radiotherapy, immunity, and immune checkpoint inhibitors.
Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024 Aug; 25(8):e352-e362.
PMID: 39089313
Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease.
Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease. J Clin Oncol. 2024 Oct 10; 42(29):3387-3391.
PMID: 39038267
STING activation disrupts tumor vasculature to overcome the EPR limitation and increase drug deposition.
STING activation disrupts tumor vasculature to overcome the EPR limitation and increase drug deposition. Sci Adv. 2024 Jul 19; 10(29):eado0082.
PMID: 39018400